Copper(I) complexes for optoelectronic devices
US-9266906-B2 · Feb 23, 2016 · US
US10494392B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10494392-B2 |
| Application number | US-201916404355-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 6, 2019 |
| Priority date | Apr 17, 2017 |
| Publication date | Dec 3, 2019 |
| Grant date | Dec 3, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Gold(I) complexes and gold(I) dithiocarbamate polymers as anticancer therapeutics. The Au(I) ion within the gold(I) complexes is coordinated to two phosphine ligands. The repeating unit formed by Au(I) ion coordinating to dithiocarbamate ligands are connected by Au(I)—Au(I) interactions within the gold(I) dithiocarbamate polymers. Also disclosed are methods of synthesis, pharmaceutical compositions incorporating the gold(I) complexes, pharmaceutical compositions incorporating the gold(I) dithiocarbamate polymers, and methods of treating cancer.
Opening claim text (preview).
The invention claimed is: 1. A method of treating cancer, comprising: administering a gold/cis-platin composition to a subject in need of therapy of at least one of lung cancer, colon cancer, and breast cancer, wherein the gold/cis-platin composition comprises cis-platin and a gold(I) complex of formula (I): or a salt thereof, a tautomer thereof, a stereoisomer thereof, or a mixture thereof, wherein R 1 , R 2 , R 3 , and R 4 are independently selected from the group consisting, of a hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, and a nitro; R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected from the group consisting of a hydrogen, an optionally substituted alkyl; and X is an anion. 2. The method of claim 1 , wherein the cancer is resistant to cisplatin. 3. The method of claim 1 , wherein 1-300 mg/kg of gold(I) complex of formula (I) is administered per body weight of the subject.
Gold compounds · CPC title
Complexes or chelates of phosphines with metallic compounds or metals · CPC title
Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795 · CPC title
Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon {with or without the latter elements in the main chain of the macromolecule} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.